Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Achieve Life Sciences Announces Phase 2b ORCA-1 Trial Data Accepted for Oral Presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference | ||
By: PR Newswire Association LLC. - 21 Jun 2019 | Back to overview list |
|
SEATTLE, Wash. and VANCOUVER, British Columbia, June 21, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company focused on nicotine addiction, today announced that an abstract featuring data from the Phase 2b ORCA-1 trial has been accepted for oral presentation at the SRNT-E Annual Conference, to be held in Oslo, September 12-14, 2019. The abstract "A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 2b Trial of Cytisinicline in Adult Smokers" and oral presentation will include updated cytisinicline data from the recently completed ORCA-1 trial. As recently reported, the 254-subject ORCA-1 dose-selection trial of cytisinicline demonstrated a statistically significant improvement in quit rates for a simplified 3.0 mg, three times daily dose administered over a 25-day treatment period. In the trial, adherence to study treatment was greater than 98.5% across all arms and cytisinicline was well-tolerated with no serious adverse events reported. Additional information on cytisinicline and the ORCA program can be found at www.achievelifesciences.com and www.orcaprogram.com. About Cytisinicline Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking. As an approved, branded product in Central and Eastern Europe for more than two decades, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction. About ORCA-1 Forward Looking Statements Achieve Contact "ORCA is a trademark of Achieve Life Sciences, Inc." 1 World Health Organization. WHO Report on the Global Tobacco Epidemic, 2017. Geneva: World Health Organization, 2017 View original content to download multimedia:http://www.prnewswire.com/news-releases/achieve-life-sciences-announces-phase-2b-orca-1-trial-data-accepted-for-oral-presentation-at-society-for-research-on-nicotine--tobacco-europe-srnt-e-19th-annual-conference-300872482.html SOURCE Achieve Life Sciences, Inc. |
||
|
||
Copyright 2019 PR Newswire Association LLC. | Back to overview list |